Related by context. All words. (Click for frequent words.) 82 Negative Syndrome 80 MADRS 78 Scale PANSS 77 YMRS 77 Rating Scale MADRS 77 Global Impression 76 Montgomery Åsberg Depression 76 Montgomery Asberg Depression 76 IRLS 76 Brief Psychiatric 76 HAMD 74 PANSS total 74 HDRS 74 BPRS 73 Global Impression CGI 73 ADAS cog 73 subscales 71 MADRS score 71 HAQ DI 71 Alzheimer Disease Assessment 71 symptom severity 71 UPDRS 70 HAM D 70 NIH CPSI 70 subscale scores 69 HAM D# 69 IRLS score 69 ADHD RS 68 CNS LS 68 IBDQ 68 nasal symptom 68 WOMAC pain 67 ADAS Cog 67 Expanded Disability Status 67 Neuropsychiatric Inventory 67 Clinician Administered PTSD 67 Psoriasis Area 67 DAS# [002] 67 QoL 67 Depression Rating Scale 67 HADS 67 subscores 67 Rating Scale 66 Crohn Disease Activity 66 WOMAC 66 IPSS 66 ADCS CGIC 66 Health Assessment Questionnaire 66 APACHE II 66 Unified Parkinson Disease 66 Hamilton Rating Scale 66 Index CDAI 66 Visual Analog Scale 66 EQ 5D 65 UPDRS motor 65 Neuropsychiatric Inventory NPI 65 Scale EDSS 65 CDAI score 65 Global Impression Severity 65 BMI z 65 Negative Symptoms 65 ADHD Rating Scale 65 Rating Scale BPRS 65 ADCS ADL 65 Y BOCS 65 Scale cognitive subscale 65 SGRQ 65 depressive symptom 65 Disease Activity 65 Severity MSCS score 64 mTSS 64 PANSS scores 64 Mania Rating Scale 64 State Examination MMSE 64 biopsy Gleason 64 NIHSS 64 Mean Symptom Complex 64 MMSE score 64 Rating Scale UPDRS 64 Pain Intensity 64 International Prostate Symptom 64 DAS# CRP 64 SELENA SLEDAI 64 CFQ R 64 cognitive affective 63 QIDS SR 63 TNSS 63 Visual Analogue Scale VAS 63 Physical Component 63 Geriatric Depression 63 Primary endpoints 63 PANSS Positive 63 Severity Index PASI 63 subscore 63 WOMAC TM 63 Impressions Improvement 63 affective psychosis 63 HOMA IR 63 mRS 63 Functioning GAF 63 IIEF 63 Brief Pain 63 Secondary endpoints included 62 VFQ 62 CDAI 62 Cronbach alpha 62 ANOVA 62 achieved statistical significance 62 Fibromyalgia Impact Questionnaire 62 mg BID dose 62 interrater reliability 62 Visual Analog 62 Cystic Fibrosis Questionnaire Revised 62 Score IPSS 62 abdominal pain abdominal discomfort 62 GERD symptom 61 FACIT Fatigue 61 Score DAS# 61 HRQoL 61 Distress Scale 61 Functional Assessment 61 Scale Cognitive Subscale 61 Pain Rating Scale 61 DAS# scores 61 Score DAS 61 Secondary efficacy endpoints 61 DLQI 61 Secondary endpoints 61 pain subscale 61 Oswestry Disability Index 61 Ocular Surface Disease 61 posttest 61 extrapyramidal symptoms 61 sd = 61 secondary efficacy endpoint 61 lumbar spine BMD 60 EDSS 60 Inventory BPI 60 point Likert scale 60 euthymic patients 60 SSRI SNRI 60 Hamilton Anxiety Scale 60 CORE OM 60 HRQL 60 Subscale 60 confidence intervals CIs 60 liver histology 60 MMSE 60 Beck Anxiety Inventory 60 Negative Symptom Scale 60 Likert scale 60 -#.# mg dL [002] 60 Score TOS 60 Secondary endpoints include 60 symptomatology 60 Depression Inventory 60 KOOS 60 baseline HbA1c 60 Erectile Function 60 urinary N telopeptide 60 Depression Scale 60 Edinburgh Postnatal Depression 60 DAS# remission 60 -#.# ± [002] 60 LOCF 60 PSQI 60 HRQOL 60 Likert pain 59 MoxDuo TM IR 59 ANCOVA 59 Rating Scale IRLS 59 intraclass correlation coefficient 59 sUA 59 PCWP 59 Main Outcome Measures 59 oxycodone CR 59 clinically meaningful improvement 59 serologically active patients 59 EDSS score 59 PASI scores 59 mg TID 59 baseline PASI 59 desvenlafaxine succinate 59 apnea hypopnea index 59 PHQ 9 59 demonstrated clinically meaningful 59 undetectable HBV DNA 59 retest reliability 59 CI -#.# 59 Glasgow Coma Scale 59 subscale 59 REYATAZ r arm 59 bronchial hyperresponsiveness 59 euthymic 59 p = .# [002] 58 Symptom Checklist 58 Pearson correlation coefficient 58 NYHA functional class 58 Status Scale EDSS 58 psychometric properties 58 Erectile Function IIEF 58 Pharmacokinetic parameters 58 fasting plasma glucose FPG 58 BILAG 58 secondary endpoint 58 Likert 58 erection hardness 58 EBMT criteria 58 subjective sleepiness 58 BPH Symptom Score 58 placebo p 58 elevated ALT 58 CIBIC plus 58 SF #v# 58 ACR# response 58 univariate 58 Epworth Sleepiness Scale 58 % Confidence Interval 58 Abnormal Involuntary Movement 58 virologic response 58 Mental Component 58 Total Nasal Symptom 58 prespecified secondary 58 Hopkins Symptom Checklist 58 Severity Index 58 achieved ACR# 58 4mg/kg 58 HbA 1c 58 Symptom severity 58 dyspnoea 58 -#.# mg dL [001] 58 Acute Physiology 58 intraclass correlation coefficients 58 emotional lability 58 haematologic 58 Depressive symptoms 58 ACR# ACR# 57 function subscale 57 Clinically meaningful 57 p = #.# [002] 57 non menstrual pelvic 57 linaclotide treated 57 Key secondary endpoints 57 PREZISTA r arm 57 lopinavir r arm 57 mcg QD 57 fasting plasma glucose 57 Numeric Rating Scale 57 Incontinence Impact Questionnaire 57 Main Outcome Measure 57 subsyndromal 57 rhinoconjunctivitis 57 adjunctive placebo 57 Epidemiologic Studies Depression 57 posttreatment 57 convergent validity 57 preoperative PSA 57 covariate 57 Ashworth Scale 57 Symptom Score 57 SELENA SLEDAI score 57 ETDRS 57 UPDRS Part III 57 RECIST Response Evaluation Criteria 57 8mg/kg 57 clinically meaningful reductions 57 multivariate Cox 57 certolizumab 57 HBeAg negative patients 57 somatic symptom 57 % CI #.#-#.# [007] 57 â ‰ ¥ 57 P = .# 57 methotrexate monotherapy 57 fasting insulin 57 HBeAg seroconversion 57 endoscopic remission 57 univariate analysis 57 somatic symptoms 57 bivariate 57 demonstrated statistically significant 57 premorbid 57 Visual Analogue Scale 57 ACR Pedi 57 exploratory endpoints 57 Histologic 57 6MWD 57 MMSE scores 57 psychosocial functioning 57 placebo p = 57 Outcomes Study 57 rheumatoid factor 57 Likert type 57 Scale EDSS score 56 fructosamine 56 baseline A1C 56 antipsychotic efficacy 56 tolterodine ER 56 serum urate 56 variance ANOVA 56 scores TNSS 56 EORTC QLQ C# 56 semiquantitative 56 tipranavir r 56 apolipoprotein B 56 Pred Forte 56 #q# deletion syndrome 56 untreated psychosis 56 Dyspnea 56 Wilcoxon rank sum 56 -#.# log# copies mL 56 Seattle Angina Questionnaire 56 #mg/day [001] 56 SSRI citalopram 56 Index CDAI score 56 logistic regression 56 BPH symptom 56 plus methotrexate 56 Descriptive statistics 56 Treatment Outcome 56 State Trait Anxiety 56 AUA Symptom Score 56 clinically meaningful improvements 56 -#.# log# 56 mcg BID 56 dyspnea 56 LVEF 56 CR CRu 56 serum phosphorous 56 adjunctive ABILIFY 56 Depression Inventory BDI 56 MS DRGs 56 prespecified 56 placebo fluoxetine 56 somatization 56 IKDC 56 Visual acuity 56 SVR# 56 erythrocyte sedimentation rate 56 -5 -6 56 HbA 1c levels 56 CANCIDAS 56 Thrombolysis 56 F FDG PET 56 Response Evaluation Criteria 56 laboratory abnormalities 56 HBeAg 56 mg QD 56 Cockcroft Gault 56 Index HAQ DI 56 p = #.# [004] 56 OGTT 56 dactylitis 56 interobserver 56 comorbid anxiety 56 TEAEs 56 NPRS 56 NIS LL 56 ug dose 56 Cronbach 56 TIMI 56 comorbid 56 depressive symptoms 56 postintervention 56 ASIA Impairment 56 CRp 56 tipranavir ritonavir 56 glycated hemoglobin 55 virological response 55 % CI #.#-#.# [006] 55 nausea photophobia 55 platelet reactivity 55 MetS 55 serum cortisol 55 retinal thickness 55 TMC# r 55 Change PGIC 55 System IPSS 55 lipid parameters 55 intraobserver 55 LEXIVA r 55 symptomatic VTE 55 WOMAC scores 55 ACR# [002] 55 CCyR 55 Assessment Scale 55 p = #.# [003] 55 dapagliflozin plus 55 binary restenosis 55 CR nPR 55 treat NNT 55 secondary efficacy endpoints 55 Negative Symptom Scale PANSS 55 affective disorders 55 Rosenberg Self Esteem 55 Flu Cy 55 Hb A1C 55 interrater 55 rimonabant #mg 55 Interrater reliability 55 spontaneous bowel movements 55 hip BMD 55 logistic regression model 55 XIENCE V PROMUS Stent 55 Sensitivity specificity 55 KCCQ 55 glycated hemoglobin HbA1c 55 solifenacin 55 BPRS PSS 55 plus MTX 55 antibody titer 55 log# copies mL 55 calculated creatinine clearance 55 nonfatal MI 55 lymphopenia 55 baseline FEV 55 annualized relapse 55 #.#/#.# mmHg [001] 55 mg XP# 55 schizophrenia schizoaffective disorder 55 serum BDNF 55 Ishak fibrosis score 55 histologic 55 IFN α 55 albumin excretion rate 55 Knodell necroinflammatory score 55 Urogenital Distress Inventory 55 intima media thickness 55 mg BID 55 methacholine challenge 55 Kruskal Wallis test 55 Platelet counts 55 gadolinium enhancing 55 multivariate analyzes 55 PDSS 55 paliperidone ER 55 syndromal 55 WAIS III 55 logistic regression analysis 55 bortezomib refractory 55 daytime somnolence 55 x ULN 55 Depressive Symptomatology 55 placebo PBO 55 atherogenic dyslipidemia 55 eNO 55 HbA 1C 55 generalized estimating 55 glycosylated hemoglobin HbA1c 55 urine albumin 55 Chronic Illness Therapy 55 hematological parameters 55 prospectively defined 55 df = 55 HbA1c levels 55 Depressive Symptoms 54 ± SEM 54 ± SD 54 ‰ ¥ 54 receiving golimumab 54 mcg Albuferon 54 alanine aminotransferase ALT 54 preoperatively 54 Index FSFI 54 bivariate analyzes 54 nonsignificant 54 enthesitis 54 lymphovascular invasion 54 depressive symptomatology 54 episodic migraine 54 = #.#-#.# 54 subthreshold depression 54 systolic BP 54 composite endpoint 54 PSADT 54 alanine aminotransferase 54 Scale CNS 54 moderate renal impairment 54 budesonide pMDI 54 unpaired t 54 psychopathological symptoms 54 receiving VICTRELIS 54 HBV DNA levels 54 atheroma volume 54 Global Impressions Severity 54 ALT elevations 54 correlation coefficients 54 morphometric vertebral fractures 54 infliximab monotherapy 54 p = .# [001] 54 CSBMs 54 Stroke Scale NIHSS 54 meta regression 54 serum potassium 54 periprocedural 54 chi squared 54 UACR 54 fasting plasma 54 ACTEMRA TM 54 biochemical recurrence 54 T2DM 54 MCyR 54 lymphocytosis 54 multivariable analysis 54 guanfacine extended release 54 LV ejection fraction 54 Symptom 54 PERMP 54 primary efficacy endpoint 54 % CI #.#-#.# [003] 54 trough FEV1 54 CIMZIA TM certolizumab pegol 54 lymphocyte count 54 INVEGA ® 54 tapentadol IR 54 CHADS 54 metabolic parameters 54 Univariate analysis 54 endometrial thickness 54 SDQ 54 tapentadol ER 54 serum HCV RNA 54 NCQA accreditation surveys 54 postdose 54 hsCRP 54 QRS duration 54 IL#B 54 Injury Severity Score 54 Symptom Severity 54 CSBM 54 gadolinium enhancing lesions 54 AUA BPH Symptom Score 54 citalopram 54 ARB telmisartan 54 statistically significant improvement 54 comorbidity 54 highly emetogenic 54 conditional logistic regression 54 mg ustekinumab 54 serum prostate 54 RE LY ® 54 incontinence episodes 54 CIMZIA ™ 54 salmeterol fluticasone propionate 54 salivary cortisol 54 prednisone prednisolone plus 54 plasma HCV RNA 54 Pearson correlation coefficients 54 plasma cortisol 54 PEPI 54 atherothrombotic disease 54 amisulpride 54 Primary Endpoint 54 FACIT 54 mean ± SEM 54 tic severity 54 glycosylated hemoglobin levels 54 serum HBV DNA 54 attain statistical significance 54 NIHSS score 54 odds ratios ORs 54 mean baseline A1C 54 hematologic parameters 54 prospectively stratified 54 #.#mg/dL 54 HbA1c 54 serum IGF 54 affective psychoses 54 achieving PASI 54 EDEMA3 trial 54 NNT = 54 PsA 54 sustained virological response 54 ß = 54 bivariate analysis 54 diameter stenosis 54 creatinine ratio 54 cEVR 54 mRNA expression 53 somatostatin analog 53 Demonstrated Significant 53 vitreous haze 53 partial remissions 53 echocardiographic parameters 53 FDA defined valvulopathy 53 Wechsler Adult 53 concomitant medications 53 vasomotor 53 cardiac autonomic 53 pCR 53 mg p = 53 HER2 expression 53 CHADS 2 53 hemoglobin A1c HbA1c 53 metformin IR 53 AGILECT ® 53 Univariate 53 SBMs 53 symptom exacerbation 53 Median PFS 53 plasma folate 53 CHADS2 53 tirofiban 53 chlorambucil 53 hepatic enzyme 53 Stroke Scale 53 schizotypal 53 MSLT 53 allele frequencies 53 LAMICTAL 53 Treatment Diabetic Retinopathy 53 covariance 53 venlafaxine XR 53 hemoglobin A1c levels 53 ug kg 53 left ventricular diastolic 53 glomerular filtration rate 53 PEG IFN 53 ALSFRS R 53 adenotonsillectomy 53 Lucentis monotherapy 53 ATACAND 53 ≥ 53 definite stent thrombosis 53 adefovir treated 53 specific antigen PSA 53 dichotomized 53 CIMZIA TM 53 International Prognostic Scoring 53 pT3 53 immunostaining 53 Kaplan Meier estimates 53 alexithymia 53 somatic complaints 53 State Exam MMSE 53 dose dependently 53 racemic albuterol 53 hyperarousal 53 multivariable Cox 53 Mini Mental 53 Kaplan Meier analysis 53 multivariate logistic regression 53 Wechsler Memory 53 tolvaptan 53 neutrophil counts 53 p = 53 statistically nonsignificant 53 achieved PASI 53 R# #mg BID 53 cytogenetic response 53 nonparametric 53 UPDRS II 53 #mg BID [003] 53 glomerular filtration 53 Non inferiority 53 RLAI 53 serum CRP 53 logistic regression analyzes 53 phonophobia 53 nonobese 53 Likert scales 53 complete cytogenetic 53 lactate dehydrogenase LDH 53 Solid Tumors criteria 53 Timed Walk 53 APTIVUS r 53 mcg albinterferon alfa 2b 53 Severity 53 HIV RNA 53 SGOT 53 CrCl 53 Virologic 53 lopinavir r 53 ALS Functional 53 Structured Clinical 53 rosuvastatin #mg 53 neutropaenia 53 aPTT 53 HBsAg 53 insulin detemir 53 IU ml 53 Functional Outcomes 53 divalproex 53 Genant modified Sharp 53 HbA1C levels 53 multiple logistic regression 53 somatoform disorders 53 transaminases 53 carotid IMT 53 lispro 53 unfractionated heparin UFH 53 mL/min/#.# m 2 53 #.#ng/ml 53 HAM D# scores 53 CIBIC + 53 % CI #.#-#.# [004] 53 active comparator 53 Solid Tumors 53 pulmonary capillary wedge 53 Outcome Measures 53 BENICAR 53 CC genotype 53 HBeAg + 53 psychosocial variables 53 RECIST criteria 53 SGPT 53 sensitivity specificity 53 Kruskal Wallis 53 ALT flares 53 log# reduction 53 AUC0 53 Bonferroni correction 53 meta analytic 53 Satisfaction Questionnaire 53 Rate ORR 52 Comorbidity 52 pramipexole 52 Functioning Scale 52 nighttime awakenings 52 quetiapine 52 fatigue asthenia 52 hypoglycemic events 52 subtests 52 Baseline characteristics 52 schizophreniform disorder 52 Female Sexual Function 52 divalproex sodium 52 aminotransferase levels 52 intact parathyroid hormone 52 #mg QD [002] 52 antidepressant efficacy 52 UPDRS scores 52 subanalysis 52 internalizing behaviors 52 -8 -9 52 serum urate levels 52 IIQ 52 abacavir lamivudine 52 Apidra ® 52 MCID 52 receiving ISENTRESS 52 Durezol 52 HAQ 52 lamivudine refractory patients 52 fractional anisotropy 52 adenoma recurrence 52 fluoxetine paroxetine 52 confirmed CCyR 52 Respiratory Symptoms 52 χ 52 microbiological eradication 52 total cholesterol LDL 52 OSDI 52 D Dimer 52 intima media thickness IMT 52 FEV ^ sub 52 CONCERTA ® 52 PREZISTA ritonavir 52 Pegasys ® 52 subthreshold 52 mm Hg diastolic 52 HRCT 52 nondepressed 52 logistic regression models 52 decompensation Child Pugh 52 mg RDEA# 52 NPH insulin 52 Castration Resistant Prostate Cancer 52 SUVmax 52 STRIDE PD 52 febrile neutropenia 52 virologic responses 52 log# IU mL 52 dysthymia 52 MDRD 52 nerve conduction velocity 52 IU mL 52 Sustained virologic response 52 Solid Tumors RECIST 52 Heritability 52 serum triglycerides 52 Perceived Stress Scale 52 genotypic resistance 52 HCV RNA 52 BENICAR HCT 52 univariate analyzes 52 #.#/#.# mm Hg [003] 52 MARINOL R 52 Neuropsychological Status 52 psychophysiological 52 psychiatric comorbidity 52 TPV r 52 aspartate aminotransferase 52 STAI 52 Profile SEP 52 intravascular hemolysis 52 Metastatic Renal Cell Carcinoma 52 T2 lesions 52 Partial Response 52 estimated glomerular filtration 52 RAPAFLO R 52 FDG-PET/CT 52 glatiramer acetate 52 LS BMD 52 serum testosterone 52 headache abdominal pain 52 events AEs 52 PSA nadir 52 aripiprazole 52 mmol L. 52 aspartate aminotransferase AST 52 progression TTP 52 Physical Function 52 evaluable subjects 52 plus OBT 52 plasma renin activity 52 microvessel density 52 clinical meaningfulness 52 Ki# 52 CD4 CD8 52 thyroglobulin 52 sensory neuropathy 52 sleep onset WASO 52 confidence interval CI 52 neurocognitive function 52 postprocedure 52 relapsed MM 52 CPAP adherence 52 highest tertile 52 undetectable HCV RNA 52 dose atorvastatin 52 ventricular tachyarrhythmia 52 detectable HCV RNA 52 headache nasopharyngitis 52 coronary stenosis 52 cells uL 52 overnight polysomnography 52 Charlson comorbidity index 52 docetaxel pretreated 52 HbA1C 52 blood Phe levels 52 mania hypomania 52 visceral adiposity 52 immunoreactivity 52 + PH# 52 creatinine clearance 52 Subjective 52 corticosteroid dose 52 nodular partial response 52 FDG uptake 52 glycosylated hemoglobin 52 incidence ≥ 52 extensive metabolizers 52 response pCR 52 SLEDAI 52 QTcF 52 Epidemiological Studies Depression 52 relapsing multiple sclerosis 52 postop 52 binary logistic regression 52 Coleman Liau 52 femoral neck BMD 52 pT2 52 #mg/day [002] 52 IQR 52 Cholinesterase Inhibitors 52 generalized anxiety disorder GAD 52 statistically significant p 52 zonisamide SR 52 alicaforsen enema 52 Meta analyzes 52 p = NS 52 proBNP 52 complete cytogenetic response 52 hypochondriasis 52 prodromal symptoms 52 Sociodemographic 51 ULORIC 51 histopathologic 51 HBV DNA 51 psychiatric morbidity 51 apo B 51 rotigotine 51 serum phosphorus 51 TIMP 1 51 EDSS scores 51 % CI #.#-#.# [005] 51 secondary endpoints 51 mITT 51 mcg linaclotide 51 morbidity mortality 51 Loss Severity 51 blood Phe 51 Pharmacodynamic 51 FSFI 51 peak VO2 51 TURBT 51 macroalbuminuria 51 mg kg dose 51 histopathological 51 Relieve Depression 51 Solid Tumours 51 splenectomized patients 51 spirometric 51 CIN2 + 51 treatment emergent adverse 51 lowest tertile 51 lymphocyte counts 51 Neuroticism 51 discontinuations 51 neuroleptic 51 Persistent Sleep 51 fluticasone salmeterol 51 COMBIVIR 51 CGIC 51 SKAMP D 51 Neuropsychological 51 urinary calcium excretion 51 Conflict Tactics 51 exhaled nitric oxide 51 coinfected patients 51 idiopathic Parkinson disease 51 treatment emergent AEs 51 TAXUS Express Stent 51 Lower Limb 51 carotid intima media 51 ziprasidone 51 EPDS 51 trials RCTs 51 ejaculatory function 51 Anxiety Rating Scale 51 postmenopausal osteoporotic women 51 IL 1ß 51 clinical endpoints 51 μg kg 51 Cystatin C 51 clinicopathological features 51 generalized anxiety disorder 51 ECOG 51 Clinical Dementia 51 μmol L 51 Child Behavior Checklist 51 diabetes mellitus DM 51 mean baseline HbA1c 51 neurocognitive functioning 51 dyssynchrony 51 multivariable logistic regression 51 serum aminotransferase levels 51 Ejection Fraction 51 Description Enhance 51 DSM IV TR 51 nonpsychotic 51 Repeatable Battery 51 radical prostatectomy RP 51 bepotastine besilate nasal spray 51 Regression analyzes 51 LV dysfunction 51 salmeterol fluticasone 51 plasma leptin 51 HER2 overexpression 51 antiretroviral naïve 51 primary efficacy endpoints 51 mmHg diastolic 51 Capacity FVC 51 DSM IV Axis 51 Severity Scale 51 CRQ 51 rs# [004] 51 paresthesias 51 pharmacodynamic 51 β blocker 51 Tumor Response 51 Pharmacokinetics PK 51 Fasting plasma glucose 51 CI #.#-#.# [001] 51 enzyme immunoassay EIA 51 serum PSA 51 periprocedural MI 51 SCr 51 albumin excretion 51 subtest 51 Cmax 51 antiepileptics 51 angiographic outcomes 51 Lupuzor ™ 51 comparator arm 51 inattention hyperactivity 51 lacosamide 51 sustained virologic response 51 irbesartan 51 urinary cortisol 51 concurrent ITP 51 triiodothyronine 51 Relapsing Remitting Multiple Sclerosis 51 sweat chloride 51 Subgroup analyzes 51 TLUS 51 Major Adverse Cardiac 51 hyperactivity impulsivity